zoledronic acid has been researched along with Complications of Diabetes Mellitus in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N | 1 |
Kajizono, M; Kitamura, Y; Matsuoka, J; Sada, H; Sendo, T; Soga, Y; Sugiura, Y | 1 |
Arnol, V; Cortizo, AM; Felice, JI; Gangoiti, MV; McCarthy, AD | 1 |
3 other study(ies) available for zoledronic acid and Complications of Diabetes Mellitus
Article | Year |
---|---|
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid | 2013 |
Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Topics: Aged; Anemia; Bone Density Conservation Agents; Bone Diseases; Denosumab; Dental Care; Diabetes Complications; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2015 |
Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.
Topics: 3T3 Cells; Alendronate; Animals; Bone Density Conservation Agents; Calcium; Calcium Channels, L-Type; Cattle; Cell Line; Diabetes Complications; Diphosphonates; Dose-Response Relationship, Drug; Glycation End Products, Advanced; Imidazoles; Mice; Osteoblasts; Osteoporosis; Pamidronate; Rats; Reactive Oxygen Species; Serum Albumin, Bovine; Time Factors; Zoledronic Acid | 2008 |